Discover, contribute and lead are our 3 key concepts.
Imagine a #movement where knowledge is created by and shared with multiple users. This suggests something more complex than a single laboratory, either large or small.
#Discover. We believe both #applied science and #fundamental research , at their best, serve the public good, empowers people around the world, and binds us together as never before. Our values speak to our commitment to advancing initiatives across Research & Development and #Translational Science topics.
#Contribute. We are not a pure science organization, but neither a pure application organization. We sit firmly at the intersection of the two and, to be successful, we always need the minds of the basic scientist and the engineer, those in universities, and those in industry.
#Lead. And we need them working together, often on a single project, in the cauldron created often by the urgency and demands of a global problem.
Chelonia Applied Science is the movement. You are the forces.
Meet the Executive Director
Since becoming director of Chelonia, Silvano Coletti (photo) has led a strategic and cultural transformation to build a leading innovation-driven company globally powered by access to the most brilliant minds and outstanding scientists. He introduced the most powerful cross-linked platform between innovation-driven companies and academia. Backed by training as engineer and executive education at Harvard Business School, Silvano is a former student of Prof.Ilya Prigogine (Nobel laureate 1977) at Institute Solvay (Belgium) and fellow at EPFL (Switzerland). He seats on boards of scientific committees and corporate advisory boards. Silvano’s passion for innovation and social entrepreneurship is evident: in addition to his career at Chelonia, he worked with the largest NGOs in Africa serving as delegate at the United Nations New York headquarter.
Nobel Prize serves scientific board of
Chelonia Applied Science
In 2013, Arieh Warshel, Distinguished Professor of Chemistry and Biology at the University of Southern California’s Dornsife College of Letters, Arts and Sciences, was awarded a Nobel Prize for Chemistry for his groundbreaking research in theoretical chemistry. Dr. Warshel holds the Dana and David Dornsife Chair in Chemistry at USC, where he has served on the faculty since 1976.
A member of the National Academy of Sciences, and a Foreign Member of the Russian Academy of Sciences, Dr. Warshel has pioneered computer simulations of the functions of biological molecules. He has authored over 500 peer-reviewed articles, including the book, Computer Modeling of Chemical Reactions in Enzymes and Solutions (Wiley Professional, 1991). He co-developed computer programs for molecular simulations which have been used extensively in different applications including the development of new pharmaceuticals.
Chelonia builds bold, unconventional programs and joins only the best in class
“For the KTUR project with its 12 partners, the engagement of regional companies is essential. Chelonia Applied Science involvement in the project will help us to achieve our goal of developing more collaboration between industry and academia in the trinational Upper Rhine Valley region.”
Dagmar Vössing, Head of Technology Transfer at Karlsruhe Institute of Technology (KIT) and Project coordinator of KTUR
The BIG RUN
On 21-23 of November 2020, the public-private Consortium Exscalate4Cov, supported by the European Commission, carried out the most complex supercomputing simulation ever realized. The objective was to simulate the behavior of the Sars-Cov-2 virus to identify the best therapeutic treatment. More than 70 billion molecules has been simulated on the 15 active interaction sites of the virus for a total of more than a thousand billion interactions evaluated in just 60 hours. This has been possible thanks to the simultaneous availability of the computing power (81 petaflops: millions of billions of operations per second) of Eni's HPC5, the most powerful industrial supercomputer in the world (based on information available November 24th, 2020), of CINECA's Marconi100, and the virtual screening software accelerated by the Politecnico di Milano and Cineca, and the Exscalate molecular library from Dompé. Using this technologies/method, it has been possible to reach the new goal of 5 million simulated molecules per second, making the most out the Supercomputing infrastructure. The data from the simulation are processed with SAS Viya using artificial intelligence techniques and advanced analytics. Results will be available in real time on the portal 1trilliondock.exscalate4cov.eu and then on the portal mediate.exscalate4cov.eu, designed in collaboration with SAS to allow scientists around the world to carry out their own simulations, benefiting from "state of the art" knowledge.
Chelonia Applied Science coordinates the scientific board of the highest level: Nobel Prize for Computational Chemistry Prof. Arieh Warshel, Rossen Apostolov Executive Director of BioExcel, European Centre of Excellence for Biomolecular Computational Research, Igor Tetko of Helmholtz Zentrum München and Prof. Yang Ye of Shanghai Institute of Materia Medica.
Frontrunners with Exscalate4COV
Thierry Breton, European Commissioner for the Internal Market, said: “The Exscalate4Cov platform brings innovation to drug discovery in Europe and worldwide. It demonstrates the value of true pan-European cooperation by joining the best capacities Europe has to offer in the fields of biomedical science and high-performance computing. We will continue to mobilise all technologies available, including artificial intelligence, to fight the coronavirus.”
Exscalate4CoV is the public-private consortium supported by the European Commission’s Horizon 2020 to counter the Coronavirus pandemic and improve the management and care of patients. At the core of Exscalate4CoV is Exscalate (EXaSCale smArt pLatform Against paThogEns), at present the most powerful and cost-efficient intelligent supercomputing platform in the world. Exscalate has a "chemical library" of 500 billion molecules and a processing capacity of more than 3 million molecules per second. The consortium, coordinated by Dompé Farmaceutici , is composed by 18 institutions from seven European countries. Chelonia is leading the project work package "Communication, Dissemination & Exploitation". CEO's Chelonia has been appointed Project Innovation Manager for the whole consortium.
The Italian pharmaceutical regulatory agency, AIFA, has greenlighted a clinical trial for the use of Raloxifene in patients with mild symptoms caused by the coronavirus.
The clinical study should validate the safety and efficiency of Raloxifene in blocking the replication of the virus in cells, and thus hold up the progression of the disease. The study will take place at the National Institute for Infectious Diseases ‘L. Spallanzani' in Rome, Italy and will also involve the Humanitas Research Hospital in Milan. In the initial phase, up to 450 participants in three separate treatment groups will be administered a 7-day treatment of Raloxifene capsules in a randomised sample.
Eran Segal and
Coronavirus Census Collective
Silvano Coletti co-authors with Eran Segal (photo) from Weizmann Institute of Science and others outstanding scientists from MIT, Broad Institute, Harvard and ETH the call-to-action "Coronavirus Census Collective" to track the spread of the novel coronavirus. The global collaboration is an open-access platform whereby voluntarily reported data can be used to predict the location of future COVID-19 outbreaks.
Meet Members of Chelonia
James Beacham, member of Scientific Committee of Chelonia, is the experimental high-energy particle physicist working with the ATLAS collaboration at CERN's Large Hadron Collider. As part of the ATLAS collaboration at CERN's Large Hadron Collider, one of the teams that discovered the Higgs boson in 2012, James Beacham is on the hunt for evidence of new particles -- dark photons, gravitons, dark matter and exotic Higgs bosons among them.
Piero Carninci, member of Scientific Committee of Chelonia, currently is Team Leader for Laboratory for Transcriptome Technology and Deputy Centre Director at the RIKEN Centre for Integrative Medical Sciences in Yokohama (Japan) and advisor at Human Technopole in Milano (Italy). Piero is responsible for the creation and development of various new technologies for DNA and RNA sequencing and analysis. He has also been involved in leading many large scale national and international initiatives, such as FANTOM, ENCODE and more recently the Human Cell Atlas.
Where You Can Meet Chelonia Soon